Acelyrin, Inc. (SLRN): Forward P/S Multiple
Can Acelyrin, Inc. (SLRN) scale the expansion of its immunology pipeline? This forward P/S chart provides the answer, where the value describes the current level. Revenues are based on izakibept sales to psoriasis patients via insurance networks, while the digitization of clinical test data for the interleukin inhibitor is now performed using software robots and precision manipulators.
SLRN (ACELYRIN Inc.): analytical breakdowns and indicator data
- current price and projected stock value:
- stock exchange capitalization data:
- issuer book value statistics:
- debt level and financial liquidity data:
Total Debt to Equity Ratio Acelyrin, Inc.|SLRN - Long-Term Liabilities to Capital|Short-Term Debt to Equity Acelyrin, Inc.|SLRN - Aggregate Debt Obligations|Debts to Book Capitalization ACELYRIN Inc.|SLRN - Long-Term Debt Volume|Company Short-Term Debt ACELYRIN|Quick Liquidity Indicator acelyrin.com
- financial results and valuation multiples details:
SLRN - Final Profit|Projected Future Earnings Acelyrin, Inc.|SLRN - Business Payback Period|Future Price to Earnings ACELYRIN, Inc.|SLRN - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple ACELYRIN Inc.|SLRN - Operating profit before deduction of amortization|Net earnings per share for the last 12 months ACELYRIN|SLRN - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months acelyrin.com|SLRN - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Acelyrin, Inc.
- revenue and sales details:
Summary company analysis:ACELYRIN SLRN
For the biopharmaceutical sector of Acelyrin, Inc. (SLRN), where capitalization is based on expectations from Phase 3 trials, it is critically important to correlate market value with expected cash flow. By analyzing the forward revenue multiple, an investor assesses the ratio of the current share price to future sales, which allows for the timely recognition of asset overheating against a backdrop of high cash burn and fierce competition from pharma behemoths.
Analysis of competing companies
Forward P/S Multiple HLN (Haleon)|Forward P/S Multiple Kenvue Inc KVUE|Verona Pharma Corp - Forward P/S Multiple|Jyong Bio (MENS) - Forward Price-to-Revenue Multiple|LGND: Forward P/S Multiple|Market Cap to Future Revenue Ratio amneal.com (AMRX)|Price-to-Projected Revenue Ratio Perrigo|Price-to-Projected Revenue Ratio ALVO|Forward Price-to-Revenue Multiple LQDA (Liquidia Technologies)|GLPG - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio ANI Pharmaceuticals ANIP|Forward Price to Sales MNKD|Amphastar Pharmaceuticals, Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio Pacira Pharmaceuticals PCRX|ARS Pharma (SPRY) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue TBPH|Forward Price-to-Revenue Multiple AQST|SCPH: Forward Price to Sales|Forward P/S Multiple TECX|Market Cap to Expected Sales Ratio Tonix Pharma|Price-to-Projected Revenue Ratio China SXT Pharmaceuticals, Inc. SXTC|EPRX: Market Cap to Projected Revenue|BioHarvest Sciences - Forward P/S Multiple|invizyne.com (EXOZ) - Forward Price-to-Revenue Multiple|ORMP (oramed.com) - Forward Price-to-Revenue Multiple|ENTX - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio MindWalk|ABVC BioPharma, Inc (ABVC) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Cumberland Pharmaceuticals (CPIX)|Price-to-Projected Revenue Ratio QNTM (quantumbiopharma.com)|Price-to-Projected Revenue Ratio FibroGen FGEN|Forward Price to Sales TELO|RANI - Price-to-Projected Revenue Ratio|SNYR (Synergy CHC Corp) - Market Cap to Projected Revenue|rallybio.com (RLYB) - Price-to-Projected Revenue Ratio|Future Price to Revenue LEXX (Lexaria Bioscience Corp.)|PULM (Pulmatrix) - Forward P/S Multiple|PTHL: Forward Price to Sales|Forward P/S Multiple APM|Forward P/S Multiple Lyra Therapeutics Inc (LYRA)|Price-to-Projected Revenue Ratio Impact BioMedical Inc IBO|Forward Price to Sales TNFA|YCBD - Price-to-Projected Revenue Ratio|PainReform Ltd (PRFX) - Forward Price-to-Revenue Multiple|CYTO: Forward P/S Multiple|Lipella Pharma (LIPO) - Forward P/S Multiple|Forward Price-to-Revenue Multiple OPTN|PIRS: Forward Price to Sales|Price-to-Projected Revenue Ratio Procaps (PROC)|PTPI - Market Cap to Future Revenue Ratio|Qilian International Holding Group Limited - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio TFFP (TFF Pharmaceuticals, Inc)
